Amplia Therapeutics Limited (ATX.AX)
AUD 0.05
(-1.89%)
AUD 0.05
(-1.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -4.5 Million AUD | 27.86% |
| 2023 | -6.24 Million AUD | -71.3% |
| 2022 | -3.64 Million AUD | -59.75% |
| 2021 | -2.28 Million AUD | -2.78% |
| 2020 | -2.21 Million AUD | -18.69% |
| 2019 | -1.86 Million AUD | 56.49% |
| 2018 | -4.29 Million AUD | 39.27% |
| 2017 | -7.07 Million AUD | -43.16% |
| 2016 | -4.94 Million AUD | 5.61% |
| 2015 | -5.23 Million AUD | -16.51% |
| 2014 | -4.49 Million AUD | -32.66% |
| 2013 | -3.38 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -4.5 Million AUD | 27.86% |
| 2024 Q2 | -1.12 Million AUD | 0.0% |
| 2024 Q4 | -3.37 Million AUD | 0.0% |
| 2023 Q4 | -3.33 Million AUD | 0.0% |
| 2023 FY | -6.24 Million AUD | -71.3% |
| 2023 Q2 | -2.91 Million AUD | 0.0% |
| 2022 Q4 | -2.32 Million AUD | 0.0% |
| 2022 Q2 | -1.32 Million AUD | 0.0% |
| 2022 FY | -3.64 Million AUD | -59.75% |
| 2021 Q4 | -1.76 Million AUD | 0.0% |
| 2021 FY | -2.28 Million AUD | -2.78% |
| 2021 Q2 | -511.21 Thousand AUD | 0.0% |
| 2020 Q4 | -1.33 Million AUD | 0.0% |
| 2020 Q2 | -885.26 Thousand AUD | 0.0% |
| 2020 FY | -2.21 Million AUD | -18.69% |
| 2019 Q2 | -717.8 Thousand AUD | 0.0% |
| 2019 Q4 | -1.15 Million AUD | 0.0% |
| 2019 FY | -1.86 Million AUD | 56.49% |
| 2018 FY | -4.29 Million AUD | 39.27% |
| 2018 Q4 | -1.8 Million AUD | 0.0% |
| 2018 Q2 | -2.49 Million AUD | 0.0% |
| 2017 FY | -7.07 Million AUD | -43.16% |
| 2017 Q2 | -3.48 Million AUD | 0.0% |
| 2017 Q4 | -3.59 Million AUD | 0.0% |
| 2016 FY | -4.94 Million AUD | 5.61% |
| 2016 Q4 | -2.8 Million AUD | 0.0% |
| 2016 Q2 | -2.13 Million AUD | 0.0% |
| 2015 Q3 | -1.3 Million AUD | 32.45% |
| 2015 Q2 | -1.93 Million AUD | -72.45% |
| 2015 Q1 | -1.12 Million AUD | 0.0% |
| 2015 FY | -5.23 Million AUD | -16.51% |
| 2015 Q4 | -3.29 Million AUD | -151.96% |
| 2014 Q3 | -1.12 Million AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q4 | -1.12 Million AUD | 0.0% |
| 2014 FY | -4.49 Million AUD | -32.66% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 FY | -3.38 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 16.312% |
| Acrux Limited | -5.8 Million AUD | 22.354% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 67.53% |
| BTC Health Limited | 1.05 Million AUD | 526.751% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 64.058% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 89.36% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 112.637% |
| Biome Australia Limited | -1.67 Million AUD | -169.635% |
| Hexima Limited | -933.87 Thousand AUD | -382.234% |
| Immutep Limited | -39.89 Million AUD | 88.712% |
| Memphasys Limited | -4.44 Million AUD | -1.383% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 102.867% |
| Noxopharm Limited | -3.57 Million AUD | -25.861% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 45.334% |
| Race Oncology Limited | -13.81 Million AUD | 67.412% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 90.608% |
| Starpharma Holdings Limited | -8.16 Million AUD | 44.844% |
| Tissue Repair Ltd | -4.13 Million AUD | -8.829% |
| Biotron Limited | -3.43 Million AUD | -31.047% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 76.451% |
| CSL Limited | 2.64 Billion AUD | 100.17% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 164.663% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -210.317% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -86.929% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 87.685% |
| Patrys Limited | -3.53 Million AUD | -27.247% |
| Orthocell Limited | -7.18 Million AUD | 37.286% |
| Imugene Limited | -149.68 Million AUD | 96.991% |
| PYC Therapeutics Limited | -37.72 Million AUD | 88.063% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 29.371% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 53.786% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 48.509% |
| Nanollose Limited | -1.15 Million AUD | -289.386% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -174.298% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 1489.054% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -57.226% |
| Nyrada Inc. | -1.38 Million AUD | -224.871% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 186.422% |
| Dimerix Limited | -17.07 Million AUD | 73.626% |
| PharmAust Limited | -9.03 Million AUD | 50.141% |
| AnteoTech Limited | -8.88 Million AUD | 49.288% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 92.322% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 74.502% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -31.045% |
| Actinogen Medical Limited | -13.04 Million AUD | 65.476% |
| Immuron Limited | -6.93 Million AUD | 35.08% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 17.813% |